Logo

Agilent to Undertake $500M Share Repurchase, Increases Dividend

Jan 17, 2013 | staff reporter

SAN DIEGO (GenomeWeb News) – Agilent Technologies today said that its board of directors has authorized the repurchase of up to $500 million of the firm's common stock during fiscal year 2013.

The company said that the new repurchase program replaces an existing stock repurchase program that had authorized the repurchase of shares to eliminate or reduce share dilution from equity programs.

Agilent finished its 2012 fiscal year on Oct. 31, 2012. It held $2.35 billion in cash and cash equivalents as of that date.

Agilent also said today that the board has authorized an increase in the firm's quarterly dividend to $.12 per share from $.10 per share. The dividend is payable on April 24 to shareholders of record as of the close of business on April 2.

Filed under

stock repurchase
Agilent
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.